APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(a)

The results add to growing enthusiasm for achieving the 'holy grail' of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.
Medscape Medical News